Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro proof-of-concept study.
For IBD, No Cardiovascular Risk Difference Between JAK, TNF Inhibitors
ORLANDO — Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis
December 20, 2024